For the first time, an experimental drug has extended the lives of men with advanced prostate cancer who are no longer responding to other treatments and are out of options for fighting the disease, a company-led study found.
The benefit was modest — an extra 10 weeks — but cancer specialists were excited because no chemotherapy until now has been shown to boost survival in such men, the Eau Claire (Wis.) Leader-Telegram reported. And like any new drug tested on worst-case patients, there are hopes it will do better when tested in men who aren’t as sick.
The drug is cabazitaxel, made by the French company Sanofi-Aventis SA. The federal Food and Drug Administration said it will give it a quick review, which means it could be on the market soon.